Literature DB >> 2396930

Progressive myopathy in hyperkalemic periodic paralysis.

W G Bradley1, R Taylor, D R Rice, I Hausmanowa-Petruzewicz, L S Adelman, M Jenkison, H Jedrzejowska, H Drac, W W Pendlebury.   

Abstract

A progressive degenerative myopathy has been well described in hypokalemic periodic paralysis but is not as widely recognized in hyperkalemic periodic paralysis. We studied four families with the latter disease in which some members developed a progressive myopathy. Episodes of paralysis were prolonged, lasting for months in some cases, and in one case paralysis was sufficiently severe to require ventilatory support. The progressive myopathy tended to develop at a time when attacks of paralysis were decreasing in frequency. Muscle biopsy specimens showed variability in fiber size, internal nuclei, and fibers with vacuoles. Electron microscopy showed myofibrillary degeneration and tubular aggregates. An abnormal biopsy specimen was more common in older patients. Our experience suggests that a progressive myopathy is as common in hyperkalemic periodic paralysis as it is in the hypokalemic disorder.

Entities:  

Mesh:

Year:  1990        PMID: 2396930     DOI: 10.1001/archneur.1990.00530090091018

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  18 in total

1.  Phenotypic heterogeneity and the single gene.

Authors:  G K Suthers; K E Davies
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

2.  Sodium and chloride channelopathies with myositis: coincidence or connection?

Authors:  Emma Matthews; James A L Miller; Malcolm R MacLeod; James Ironside; Gareth Ambler; Robin Labrum; Richa Sud; Janice L Holton; Michael G Hanna
Journal:  Muscle Nerve       Date:  2011-06-22       Impact factor: 3.217

3.  A novel syndrome of episodic muscle weakness maps to xp22.3.

Authors:  M M Ryan; P Taylor; J A Donald; R A Ouvrier; G Morgan; G Danta; M F Buckley; K N North
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

4.  Permanent myopathy caused by mutation of SCN4A Metl592Val: Observation on myogenesis in vitro and on effect of basic fibroblast growth factor on the muscle.

Authors:  Yu Feng; Hong Wang; Xiao-Guang Luo; Yan Ren
Journal:  Neurosci Bull       Date:  2009-04       Impact factor: 5.203

Review 5.  Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.

Authors:  Daniel Platt; Robert Griggs
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

Review 6.  Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

7.  Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness.

Authors:  Lawrence J Hayward; Joanna S Kim; Ming-Yang Lee; Hongru Zhou; Ji W Kim; Kumudini Misra; Mohammad Salajegheh; Fen-fen Wu; Chie Matsuda; Valerie Reid; Didier Cros; Eric P Hoffman; Jean-Marc Renaud; Stephen C Cannon; Robert H Brown
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 8.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

9.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

10.  Measuring quality of life impairment in skeletal muscle channelopathies.

Authors:  V A Sansone; C Ricci; M Montanari; G Apolone; M Rose; G Meola
Journal:  Eur J Neurol       Date:  2012-05-19       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.